LyGenesis
Company
LyGenesis develops 4 assets, the furthest in phase 2 (Liver in end-stage liver disease). Mostly cell therapy.
- 4
- Assets
- Furthest stage
- Phase 2
- Raised
- US$27.9m
- 0
- Trials
- 0
- Signals
Pipeline
4Allogeneic liver cells engraft in lymph nodes and grow into functioning ectopic liver tissue.
Phase 2, Cell therapy, end-stage liver disease
Allogeneic cells engraft in lymph nodes to form functioning ectopic organs.
Preclinical, Cell therapy, end-stage renal disease
Allogeneic cells engraft in lymph nodes to form functioning ectopic organs.
Preclinical, Cell therapy, type 1 diabetes
1 more asset
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Funding rounds and grants4
- People9
- Similar companies6